Correlation of HER2 codon 655 polymorphism with cardiotoxicity risk in Chinese HER2-positive breast cancer patients undergoing epirubicin/cyclophosphamide followed by docetaxel plus trastuzumab adjuvant chemotherapy.

In conclusion, HER2 codon 655 A>G was an independent predictive factor for increased cardiotoxicity risk in HER2-positive breast cancer patients undergoing EC-D-T adjuvant chemotherapy. PMID: 32211111 [PubMed]

https://www.ncbi.nlm.nih.gov/pubmed/32211111?dopt=Abstract

Source: International Journal of Clinical and Experimental Pathology - March 28, 2020 Category: Pathology Authors: Tan L, Su X, Li X, Li H, Hu B Tags: Int J Clin Exp Pathol Source Type: research